Health Care • Medical Specialities
$158.92 ▲ +1.04
(+0.66%)
MKT CAP: $7.10B • VOL: 761.5K
52W L $42 52W H $166
GRAL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $147.2M | $125.6M | $93.1M |
| YoY Revenue Growth % | +17.2% | +34.9% | — |
| Gross Profit | $64.8M | $55.3M | $41.0M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$562.2M | -$2.19B | -$1.52B |
| Operating Margin % | -382.0% | -1743.0% | -1627.6% |
| Net Income (GAAP) | -$408.4M | -$2.03B | -$1.47B |
| EBITDA (Normalized) | -$561.4M | -$2.18B | -$1.51B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$299.0M | -$577.2M | -$595.8M |
| Capital Expenditures (CapEx) | $909.0K | $5.2M | $4.2M |
| Free Cash Flow (FCF) | -$299.9M | -$582.4M | -$600.0M |
| FCF Margin % | -203.8% | -463.7% | -644.4% |
| Return on Invested Capital (ROIC %) | -17.9% | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $249.7M | $214.2M | $429.5M |
| Total Debt (Short + Long Term) | $154.9M | $216.0M | $913.6M |
| Total Stockholders' Equity | $2.58B | $2.50B | $1.87B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GRAL.